Medtronic plc (MDT)
| Market Cap | 112.94B |
| Revenue (ttm) | 33.00B |
| Net Income (ttm) | 4.29B |
| Shares Out | 1.28B |
| EPS (ttm) | 3.27 |
| PE Ratio | 26.97 |
| Forward PE | 15.47 |
| Dividend | $2.80 (3.18%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 7,682,958 |
| Open | 87.25 |
| Previous Close | 87.16 |
| Day's Range | 87.14 - 88.63 |
| 52-Week Range | 75.96 - 92.68 |
| Beta | 0.84 |
| Analysts | Hold |
| Price Target | 93.67 (+6.35%) |
| Earnings Date | Feb 18, 2025 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accesso... [Read more]
Financial Performance
In 2024, Medtronic's revenue was $32.36 billion, an increase of 3.64% compared to the previous year's $31.23 billion. Earnings were $3.68 billion, a decrease of -2.18%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for MDT stock is "Hold." The 12-month stock price forecast is $93.67, which is an increase of 6.35% from the latest price.
News
Medtronic plc (MDT) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Medtronic plc (NYSE:MDT) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 5:15 PM ET Company Participants Geoff Martha - Chief Executive Officer Sean Salmon - EVP & President, Card...
Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System
National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term ...
Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -...
Medtronic: Scoop Up This Dividend Aristocrat On Sale Now
Shares of Medtronic have lagged the S&P 500 index in the months since my previous article. The company's revenue and non-GAAP EPS grew during its fiscal Q2. Medtronic boasts an A credit rating from S&...
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries Kuros will work collaboratively to se...
Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
GALWAY, Ireland , Jan. 6, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual J.P. Morgan healthcare confere...
Medtronic: A Dividend Aristocrat That's Poised To Pop
Medtronic offers value and income potential with a 3.5% dividend yield, strong fundamentals, and 47 years of consecutive dividend increases. Despite recent share price underperformance, MDT shows soli...
2 Cheap Dividend Aristocrats to Buy for 2025
#Morningstar #DividendArtisocrats #StockInvesting These reliable dividend stocks look significantly undervalued today. 00:00 Introduction 00:39 Federal Realty Trust FRT 01:25 Medtronic MDT Susan Dziu...
My Best Dividend Aristocrats For January 2025
The ProShares S&P 500 Dividend Aristocrat ETF rocked a cool 4.85% gain in November, but it's giving up nearly half of its return this year in December. I present 3 strategies that can theoretically be...
Medtronic Stock Is Still A Great "Buy"
Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 results ...
Medtronic announces cash dividend for third quarter of fiscal year 2025
GALWAY, Ireland , Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal y...
Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain
Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up ...
Should You Pick Medtronic Stock At $85?
Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings exceeding the street estimates. The company reported revenue of $8.4 billion and ...
Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland , Nov. 20, 202...
Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Medtronic plc reported Q2 earnings today, with revenues of $8.4bn, up 5% year-on-year, adjusted EPS of $1.26, supported by a dividend yielding 3.2%. Despite consistent mid-single-digit revenue growth ...
Gold Moves Higher; Medtronic Posts Upbeat Results
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
Medtronic plc (MDT) Q2 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT) Q2 2025 Earnings Conference Call November 19, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim C...
Medtronic lifts annual profit view on strong demand for medical devices
Medtronic lifted the lower end of its annual profit forecast for a second time, banking on sustained demand for its medical devices in the U.S. and sending its shares up nearly 2% in premarket trading...
Medtronic reports second quarter fiscal 2025 financial results
Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuro...
Dividend Income: Lanny's October 2024 Summary
Big Oil with BHP Billiton came big with a massive dividend. Canadian Imperial, one of the big 6 Canadian banks, sent a massive $210 dividend my way. There are a few less names now in 2024 than 2023, s...
Beverly Hills surgeon sues Medtronic for patent infringement
A Beverly Hills surgeon is suing Medtronic claiming patent infringement of her hernia repair mesh product. It's the latest in a series of patent challenges against Medtronic.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...